Propanc Biopharma completed a 28-day toxicity study showing that PRP, the company’s lead product, showed no toxicological findings after administration.

Propanc Biopharma (OTCQB:PPCH) completed a 28-day toxicity study showing that PRP, the company’s lead product, showed no toxicological findings after administration.
As quoted in the press release:

PRP is a combination of pancreatic proenzymes trypsinogen and chymotrypsinogen in solution, for once daily intravenous administration.
The GLP-compliant study was conducted by the Company’s contract research partner, vivoPharm Pty Ltd, in Melbourne, Australia.
“We are delighted to have completed this important milestone, which is pivotal for supporting a clinical trial application in the UK, which we expect to submit later this year,” said James Nathanielsz, Propanc’s Chief Executive Officer. “We have now officially entered the clinical development stage for our lead product, PRP, which represents an exciting new therapeutic approach for the treatment and prevention of metastatic cancer.”

Click here to read the full press release.

Source: www.marketwired.com

australia biopharma cancer chymotrypsinogen james nathanielsz pancreatic proenzymes trypsinogen propanc propanc biopharma prp toxicity study Pharmaceutical Investing